Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1083-1093

  Ou, Sai Hong Ignatius ^a,b,c   Ziogas, Argyrios ^b,c   Zell, Jason A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asian ethnicity; California Cancer Registry; Epidemiology; Hispanic ethnicity; Never smoker; Non small cell lung cancer; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASIAN; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; ETHNICITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SMOKING HABIT; TREATMENT DURATION; UNITED STATES;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SMOKING; SOCIOECONOMIC FACTORS;

EID: 69549121734     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b27b15     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-790. (Pubitemid 47463669)
3. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-570. (Pubitemid 350002964)
4. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never-smoked. Lancet Oncol 2008;9:676-682. (Pubitemid 351878053)
5. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-2251. (Pubitemid 46630653)
6. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-192. (Pubitemid 47068220)
7. Dibble R, Langeburg W, Blair S, et al. Natural history of non-small cell lung cancer in non-smokers. J Clin Oncol 2005;23(16S):7252.
8. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351. (Pubitemid 39093415)
9. Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:827-830. (Pubitemid 47361024)
10. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival in stage I nonsmall cell lung cancer patients. Cancer 2007;110:1532-1541.
11. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer 2008;112:136-143.
12. Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol 2008;3:216-227.
13. Zell JA, Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005;23:8396-8405.
14. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Low socioeconomic status independently portends poor survival in stage I non-small-cell lung cancer. Cancer 2008;112:2011-2020.
15. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never-smokers. J Clin Oncol 2007;25:472-478.
16. Green LS, Fortoul TI, Ponciano G, Robles C, Rivero O. Bronchogenic carcinoma in patients under 40 years old: the experience of a Latin American country. Chest 1993;104:1477-1481. (Pubitemid 23327867)
17. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
18. Pirker B, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(20 suppl):Abstract 3.
19. Mok TS, Leong S, Liu X, et al. Gefitinib vs carboplatin/paclitaxel in clinically selected chemonaive patients with advanced non-small-cell lung cancer in Asia (IPASS): randomized, open-label, phase III study. J Thorac Oncol 2008;3(Suppl 4):S302.
20. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008;372:1809-1818.
21. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855. (Pubitemid 47181391)
22. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Thorac Oncol 2008;3:590-598.
23. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systemic review with meta-analysis. Eur Respir J 2002;20:975-981. (Pubitemid 35175137)
24. Liu W, Innicenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012. (Pubitemid 36323704)
25. Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PloS Med 2007;4:e125. (Pubitemid 46658773)
26. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006;1:406-412. (Pubitemid 47181415)
27. Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 1999;17:2086-2091. (Pubitemid 29318839)
28. Powell CA, Spira A, Derti A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol 2003;29:157-162. (Pubitemid 36936642)
29. Dutu T, Michiels S, Fournet P, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 2005;16:1906-1914. (Pubitemid 41724279)
30. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-1688. (Pubitemid 46622139)
31. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181. (Pubitemid 46316032)